Doctor of Osteopathy Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Luke Ennis

Hospitalist Roanoke, VA Doctor of Osteopathy

NPI 1184121279 CMS profile 9915861

3 Riverside Cir, Roanoke, VA 24016

Open in the dashboard

General payments

$1,129

68 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Luke Ennis of Roanoke, VA is reported in the CMS Open Payments database as having received $1,129 across 68 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $236 14
2022 General $616 37
2021 General $277 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luke Ennis
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Luke Ennis were reported at $0. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Luke Ennis Hospitalist median Middle half National median
2019 $0 $96 $28–$201 $163
2020 $0 $48 $19–$125 $114
2021 $277 $70 $23–$167 $132
2022 $616 $85 $27–$174 $149
2023 $236 $89 $30–$191 $160
2024 $0 $95 $29–$204 $164
2025 $0 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Pfizer Inc. $305 18 payments
  2. Novartis Pharmaceuticals Corporation $210 14 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $135 7 payments
  4. Janssen Pharmaceuticals, Inc $98 7 payments
  5. E.R. Squibb & Sons, L.L.C. $92 5 payments
  6. AstraZeneca Pharmaceuticals LP $88 6 payments
  7. Alexion Pharmaceuticals, Inc. $75 4 payments
  8. Gilead Sciences, Inc. $49 2 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $33 2 payments
  10. Paratek Pharmaceuticals, Inc. $17 1 payment
  11. Other $28 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $1,129 68 payments
Products named General payments · program years 2021–2023
  1. ELIQUIS Cardiovascular;Metabolic Disease $305 18 payments
  2. ENTRESTO Cardiovascular $148 10 payments
  3. JARDIANCE $135 7 payments
  4. XARELTO $98 7 payments
  5. LOKELMA $88 6 payments
  6. ELIQUIS Cardiovascular $72 4 payments
  7. LEQVIO $63 4 payments
  8. ENTRESTO Cardiology/Vascular Diseases $63 4 payments
  9. STIOLTO RESPIMAT $60 3 payments
  10. PAXLOVID $49 3 payments
  11. Other $267 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$49,288

Medicare's payments for the services billed

Medicare patients

151

Average age 77

Services billed

601

77 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Heart failure 54%
Chronic kidney disease 51%
Ischemic heart disease 46%
Diabetes 45%
Atrial fibrillation 44%
Depression 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

68 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record